Immuron Ltd — Regulatory Filings 2017

Jun 25, 2017

PRESS RELEASE: JUNE 2017

==> picture [58 x 42] intentionally omitted <==

ABN: 80 063 114 045

Level 3, 62 Lygon Street, Carlton, Victoria, AUSTRALIA 3053 www.immuron.com I Phone: + 61 (0)3 9824 5254 I Facsimile: + 61 (0)3 9822 7735

==> picture [562 x 97] intentionally omitted <==

Change of Address

26 June 2017, Melbourne, Australia

In accordance with Listing Rule 3.14, the Company advises that the Registered Office will change effective immediately. The new address is detailed below:

Registered Office

Level 3 62 Lygon Street Carlton Vic 3053 Australia Phone: +61 (0) 3 9824 5254 Postal address: P.O. Box 655 Carlton South Vic 053

The office is staffed during normal business hour (Monday to Friday) from 08.30 to 17.00 AEST.

==> picture [61 x 47] intentionally omitted <==

Phillip Hains Company Secretary \

ABOUT IMMURON:

Immuron Ltd (ASX: IMC; NASDAQ: IMRN) is a microbiome company focused on developing and commercialising oral immunotherapeutics for the treatment of many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The Company currently markets and sells Travelan® for the prevention of travellers’ diarrhoea, whilst its lead product candidate IMM-124E is in Phase 2b clinical trials for NASH and ASH. These products together with the Company’s other preclinical immunotherapy pipeline products targeting immune-related diseases currently under development, will meet a large unmet need in the market. For more information visit: http://www.immuron.com

ABN: 80 063 114 045

Level 3, 62 Lygon Street, Carlton, Victoria, AUSTRALIA 3053 www.immuron.com I Phone: + 61 (0)3 9824 5254 I Facsimile: + 61 (0)3 9822 7735